Light-mediated remote control of signaling pathways by Priestman, Melanie A. & Lawrence, David S.
Light-Mediated Remote Control of Signaling Pathways
Melanie A. Priestman and David S. Lawrence*
Departments of Chemistry, Medicinal Chemistry & Natural Products, and Pharmacology, The
University of North Carolina at Chapel Hill, Kenan Laboratories, Campus Box 3290, Chapel Hill, NC
27599-3290
Summary
Cell signaling networks display an extraordinary range of temporal and spatial plasticity. Our
programmatic approach focuses on the construction of intracellular probes, including sensors,
inhibitors, and functionally unique proteins that can be temporally and spatially controlled by the
investigator even after they have entered the cell. We have designed and evaluated protein kinase
sensors that furnish a fluorescent readout upon phosphorylation. In addition, since the sensors are
inert (i.e. cannot be phosphorylated) until activated by light, they can be carried through the various
stages of any given cell-based behavior without being consumed. Using this strategy, we have shown
that PKCβ is essential for nuclear envelope breakdown and thus the transition from prophase to
metaphase in actively dividing cells. Photoactivatable proteins furnish the means to initiate cellular
signaling pathways with a high degree of spatial and temporal control. We have used this approach
to demonstrate that cofilin serves as a component of the steering apparatus of the cell. Finally,
inhibitors are commonly used to assess the participation of specific enzymes in signaling pathways
that control cellular behavior. We have constructed a photo-deactivatable inhibitor, an inhibitory
species that can be switched off with light. In the absence of light, the target enzyme is inactive due
to the presence of the potent inhibitory molecule. Upon photolysis, the inhibitory molecule is
destroyed and enzymatic activity is released.
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Introduction
The remarkable complexity of life entails intricately tuned cascades of biochemical events in
individual cells, tissues and whole organisms. Signal transduction pathways mediate the
cellular response to environmental factors, such as pH, ions, electromagnetic radiation, and the
wide assortment of cell-derived stimuli (neurotransmitters, growth factors, secondary
messengers). With the sequencing of the human genome in 2001,[1,2] there were great
expectations that the information gained could be used to correlate gene expression with
biochemical activity and thus with normal and aberrant (i.e. disease) cell-based behaviors.
However, complete insight into the necessary events that initiate and maintain normal and
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diseased states requires not just DNA sequences, but also an understanding of the interplay of
gene expression in the context of protein inhibition, activation, and recycling.
Advances in technology have lead to significant improvements in our understanding of
intracellular chemistry, especially in the fields of epigenomics and proteomics. Although these
disciplines have generated a vast array of information about gene expression and protein
activity, they do not lend themselves to investigating the action of specific signaling molecules,
genes, or proteins at the single cell level. Several methods have been developed to address how
gene expression influences cellular events, including overexpression or knock down of the
gene of interest. Molecular biology has also provided a unique set of fluorescent proteins, most
notably an array green fluorescent protein (GFP) analogs, that can be used to produce
fluorescent protein constructs that can monitor the location of a specific protein within an
individual cell [3]. Furthermore, chemists have supplied numerous small molecule activators,
inhibitors and sensors to this expanding biological toolbox, which have been used to alter or
monitor protein activity. Despite the fact that these innovations have led to a better
understanding of cellular events, these tools are generally unable to probe or manipulate the
biochemistry of life with a high degree of spatial or temporal control.
Cellular states and events like homeostasis, mitosis and apoptosis all involve precise timing of
gene transcription, protein activation, inactivation and degradation. Along with temporal
control, cellular events are often spatially restricted to subcellular organelles, the cytoskeletal
network, or cellular extensions, allowing activation of specific signaling networks in a spatially
confined region of the cell. In order to address the spatiotemporal aspects involved in signaling
cascades, photoactivatible or “caged” compounds have been developed for the precise time-
dependent release of the bioactive molecule. Caged compounds are biologically inert until they
absorb one or more photons of light, thereby liberating a bioactive molecule, be it a protein, a
genetic coding sequence, an inhibitor, activator, or sensor. ATP and cAMP were the first caged
compounds to be described [4,5]. Caged compounds have been developed as effectors of (i)
gene expression, (ii) protein expression, (iii) protein activation, (iv) fluorescence, (v) protein
inhibition (vi) biochemical sensing [6–22]. Our lab has primarily focused on the design,
synthesis, and characterization of caged compounds for elucidating the spatiotemporal
dynamics of signaling pathways.
Chemistry of Photoactivatible Molecules
Temporal or spatial control of a bioactive species (gene, protein, etc) is readily afforded by
introducing a photolabile group at a site on the molecule of interest required for biological
activity. Caged compounds are commonly activated by absorbance of one or more photons,
thereby resulting in the cleavage of the photolabile group and restoration of biological activity.
More recently, the term caging has also been used in reference to photoswitches, which undergo
isomerization resulting in a reversible conformational change that alters activity. Azobenzene
moieties and spiropyran-based functionality have been utilized to generate photoswitches in
peptides[23–28], peptidomimetics[29], proteins[6,9,30–36] and nucleic acids[16,37,38]. In
addition, photoactivatible derivatives of GFPs have been described which display
photoinduced fluorescence increases [39–48]. Recently a genetically-encoded caging strategy
using a photosensory domain from phytochrome B has been described to cage WASP.[49]
Caged molecules require (i) the introduction of a photolabile moiety on a functional group that
is essential for biological activity, (ii) biologically inertness, and (iii) light-driven formation
of the active species in the absence of toxic byproducts. A large number of photolabile groups
have been developed as caging moieties and the vast majority of these are photolyzed at
wavelengths less than 365 nm [8,12,13,20,50]. The most commonly used photocleavable
species are the ortho-nitrobenzyl, hydroxyphenacyl, coumarin, cinnamate moieties, and their
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derivatives. The mechanism of photolysis for the ortho-nitrobenzyl group involves absorption
of a photon to generate an aci-nitro intermediate (Scheme 1). The latter is rapidly converted
to a hemiacetal, which decomposes to furnish the free biologically active molecule and a
nitrosobenzene byproduct (Scheme 1). Aldehyde byproducts from this reaction are
electrophilic and therefore may have deleterious intracellular consequences. By contrast,
ketone byproducts are generally considered to be biologically inert [5].
Two key parameters that must be considered when dealing with photolabile groups are
wavelength of activation and quantum yield (Φ) of uncaging. Caging moieties that suffer
photolysis at wavelengths less than 300 nm are not regarded as biologically useful because of
the toxicity associated with UV light. Although derivatives of the ortho-nitrobenzyl group have
been developed that absorb at longer wavelengths (>360 nm) they display a striking decrease
in quantum yield [51]. At these short wavelengths photons are absorbed by cellular
chromophores and thus do not penetrate deeply enough into samples to be effective in whole
tissues or live animals. Photolabile groups with longer uncaging wavelengths, such as coumarin
derivatives that absorb at 400 nm[52,53], or those that contain a large two photon cross section
[54–59] have been identified. The field of uncaging awaits the development of multiple
photolabile groups that are sensitive to longer wavelengths as well as the creation of additional
two photon responsive caging groups that can be applied in live animals.
Photoactivatable Proteins
Perturbation of intracellular protein levels provides an understanding of how specific proteins
influence cell behavior. However, changes in expression levels do not always correlate with
changes in activity. Protein activity is regulated by an intricate network of signaling pathways
that serve as both on and off signals for cellular processes. A host of techniques have been
developed to address how an active or inactive protein influences cellular chemistry, including
site-directed mutagenesis to generate constitutively active proteins or dominant negative
constructs. However, these strategies do not address the time-dependent nature of signaling
cascades. By contrast, a caged derivative of a protein allows for precise control over where
and when the protein of interest is activated. Over the last two decades a number of methods
have been utilized to create caged proteins: (i) covalent modification of an existing nucleophilic
residue on the protein with a photolabile group, (ii) insertion of an appropriate reactive residue
at the desired position via site-directed mutagenesis, (iii) enzyme-catalyzed site-specific
introduction of reactive functionality[60], (iv) construction of semisynthetic proteins via
expressed protein ligation[61–63], (v) insertion of caged amino acids via unnatural amino acid
mutagenesis[64], and (vi) genetic methods that employ a photosensory domain[49].
The cAMP-dependent protein kinase (PKA) is arguably the best mechanistically and
structurally understood of all protein kinases [65]. Binding of cAMP to the holoenzyme, a
tetramer consisting of two regulatory and two catalytic subunits, releases the catalytic subunits
that are now free to phosphorylate substrates. The catalytic subunit contains two cysteine
residues. Cys199 is located at the edge of the active site and Cys343 is positioned on the surface
far removed from the active site region.
We designed an active-site directed peptide (3) that selectively labels PKA at Cys199 [66].
The affinity of the active site directed peptide for PKA is relatively weak (KD ~ 1 mM).
Consequently, following photolysis the released peptidic species does not serve as an effective
inhibitor of PKA. The peptide backbone of 3 was prepared via standard Fmoc solid-phase
synthesis (Scheme 2). The ethylene diamine moiety (see compound 1) serves as a linker to
situate the caging group adjacent to Cys199 once the peptide is bound to the active site. The
free primary amine on peptide 1 was coupled to the caging unit 2 to generate the desired active
site directed affinity label 3. Cys199 of the catalytic subunit was modified in a time-dependent
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fashion by 3 (KI = 1.5 ± 0.3 mM) to generate caged (i.e. inactive) PKA 4. Electrospray
ionization mass spectrometry revealed a single alkylation of PKA confirming the active site
delivery of the caging group to Cys199. In vitro analysis of PKA revealed that 4 has less than
2% residual activity and a 25-fold enhancement in activity after photolysis. Although only 50%
of the native activity is recovered after uncaging, the 25-fold difference in activity before and
after photolysis proved sufficient for subsequent intracellular studies.
Activation of PKA by cAMP or injection of free catalytic subunit in fibroblasts is known to
induce conversion from an extended to rounded cellular morphology as well as loss of actin-
containing stress fibers [67]. Rat embryo fibroblasts (REF) cells were microinjected with 3 –
7 μM of caged PKA catalytic subunit or its free active counterpart. After microinjection, cells
were illuminated with a 200 W Hg arc lamp and placed in an incubator for 1 h. The cells were
subsequently fixed for immunofluorescence with rhodamine-labeled phalloidin, which binds
to F-actin found in stress fibers. Microinjected, but non-illuminated, REF cells display a similar
morphology and stress fiber network as their non-microinjected counterparts (Fig a). However,
upon photolysis, cells containing caged PKA exhibit membrane ruffling, a rounded
morphology (Fig 1b), and a loss of stress fibers. These are all characteristics of an activated
PKA signaling cascade. Similar results were obtained when free catalytic subunit was
microinjected (Fig 1c). In addition, photolysis without microinjection of the caged enzyme,
failed to produce any changes in cellular morphology.
In addition to regulation by small molecule activators such as cAMP, many members of
signaling pathways are turned on or off by protein kinases or phosphatases. Consequently,
photoactivation of a caged signaling protein may be transient at best due to the presence these
regulatory enzymes. In order to circumvent this potential difficulty, we constructed a caged
signaling protein that, upon photolysis, generates a constitutively active species that is not
regulated (bio-orthogonal) by the endogenous biochemistry (i.e. kinases and phosphatases) of
the cell.
Epidermal growth factor (EGF) stimulates cell motility, a behavior that is dependent, at least
in part, on the intracellular protein cofilin. However, the specific role played by this protein
kinase-regulated species in growth factor-directed motility is unclear. The initial step in
chemotaxis is the formation of a lammelipod, a membrane protrusion driven by actin
polymerization [i.e. the conversion of monomeric G (globular) actin into polymeric F
(filamentous) actin]. Cofilin is known to control actin dynamics in living cells, by altering the
equilibrium between the G and F actin states. Cofilin both cleaves and promotes the
depolymerization of F-actin. The latter suggests that, in its active state, cofilin should block
lammelipod formation by breaking down F-actin and thus inhibit motility. On the other hand,
the newly cleaved F-actin contains “barbed ends” that, in the presence of a sufficient supply
of G-actin, serve as initiation sites for filament elongation. Under these conditions, active
cofilin should enhance lammelipod formation by inducing actin polmerization and thus
promote cell motility. In short, cell free in vitro studies have implicated cofilin in both F-actin
polymerization and depolymerization depending upon the supply of G-actin [68,69]. Based on
these in vitro results, it is simply unclear whether intracellular cofilin activity blocks or
promotes lammelipod formation. Cofilin activity is regulated by phosphorylation at Ser3. LIM
kinase catalyzed phosphorylation inactivates cofilin, whereas dephosphorylation restores
activity (Fig 2).
In order to address the role of cofilin in cell motility, we generated a photo-regulated cofilin
that could be switched on at anytime and anywhere in a live cell [70,71]. Site-directed
mutagenesis of Ser3 to Cys in cofilin generates a protein that maintains a high rate of F-actin
severing but cannot be phosphorylated by LIM kinase, thereby rendering cofilin constitutively
active. Caged cofilin was synthesized by covalently modifying Cys3 with the same ortho-
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nitrobenzyl moiety (2) used to cage PKA, which introduces a negatively charge carboxyl group
that mimics the electrostatic state of the inactive phosphorylated cofilin (Fig 2). Mass
spectroscopy confirmed covalent modification of the Ser-to-Cys cofilin at a single site, a
modification that is removed upon irradiation at 365 nm. SDS-PAGE of sedimentation assays
revealed that the caged cofilin is unable to bind to F-actin. However, upon photolysis F-actin
binding is restored. The ability of the caged versus uncaged cofilin to sever F-actin was tested
using two assays: (i) a spectrofluorimetric assay for F-actin depolymerization and (ii)
microscopic imaging of F-actin cleavage using a fluorescently labeled actin. Caged cofilin has
no effect on F-actin depolymerization (versus buffer alone), but photolysis restores up to 80%
of the F-actin severing activity (Fig 3).
The caged cofilin construct was microinjected into MTLn3 cells to assess the effect of spatially-
and temporally-confined cofilin activity on actin polymerization and depolymerization, leading
edge protrusion, and motility. A 36% increase in the cellular level of F-actin was observed
after whole cell photoactivation of caged cofilin for 0.5 s using a 100 W Hg arc lamp directed
through the 40X oil objective. As expected, the increase in cellular F-actin after photolysis of
caged cofilin also increases the production of barbed ends. Photoactivation of cofilin in MTLn3
cells produced an increase in the size of the lamellipods as well as the velocity of their
formation. In order to assess if cofilin activity affects localized protrusions of lamellipodia or
can influence the directionality of motility, uncaging was carried out in a 3 μm diameter spot
and cell movement monitored by time lapse photography. Cell protrusions were observed near
the spot of irradiation in approximately 80% of all cells microinjected with caged cofilin
compared to just 4% of non-injected cells (Fig 4). Cells that were not loaded with caged cofilin
show a directionless random walking in serum, whereas 70% of cells that have photoreleased
cofilin move in the direction of spot illumination. These intracellular experiments confirm that
cofilin produces free barbed ends, leads to cell protrusions, and sets the direction of motility.
A wide variety of caged proteins have been described. However, only a small fraction of these
proteins have actually been evaluated in living cells (or cell lysates). Furthermore, the
overwhelming majority of these cell-based experiments were primarily performed to validate
the light-dependent activity of the caged protein rather than to address a biological question.
Given the potential advantages associated with these light activated species, it is somewhat
surprising that caged proteins have not found more widespread application. The limited number
of cellular studies is partly due to the difficulties associated with the preparation of these caged
species. As noted above, a number of methods have been developed to introduce a
photocleavable moiety at a specific site on the protein to be caged. However, mere modification
at a specific site on the protein of interest does not necessarily furnish an ideal caged protein
for intracellular studies. For example, issues that often need to be addressed are (i) acquisition
of caged protein that, upon photolysis, exhibits a dramatic change in activity (i.e. from little or
no activity to nearly fully active), (ii) introduction of appropriate post-translational
modifications (including phosphorylation) that may be required for intracellular function, (iii)
cellular delivery of the caged protein, (iv) and elimination (or reduction) of endogenous wild
type activity that the caged protein is designed to replace. However, in our opinion, the primary
reason for the limited application of caged proteins as biological tools is the absence of input
from biologists in the design of these species. The preparation of caged proteins is currently
an art form practiced primarily by members of the chemical community. By contrast, the design
of specific photosensitive protein constructs to address the temporal and spatial consequences
of protein action in living cells is best achieved in consultation with biologists.
Light-Driven Small Molecule Activation of Proteins
In addition to caged proteins, caged cell-permeable small molecule activators of protein
function have been developed. However, although the activity of caged low molecular weight
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compounds can be unleashed with a high degree of temporal control, spatial control at or below
the cellular level is not feasible due to the high diffusion rate of small molecules. As noted in
the Introduction, one of the first caged compounds ever reported was that of cAMP[4], the
activator of the cAMP-dependent protein kinase. In addition, since this initial report, a number
of caged neurotransmitters, hormones, small molecule agonists, and peptides have been used
to activate signaling cascades [8,12,17,20].
The majority of caged peptides have been synthesized by modifying key side chain
functionality, which usually requires an off-resin, multistep process that is not amendable to
all amino acid groups. We designed an on-resin caging strategy that places the photolabile unit
on the backbone amide nitrogen adjacent to a key binding site residue [72]. The backbone-
bound photolabile group disrupts proper alignment of active site-targeted functionality,
rendering the peptide ineffective. Two other reports have described peptides caged on the
backbone, one at a backbone-substituted glycine and one using an N-benzylated protecting
group[73,74].
Src family tyrosine kinases are comprised of an SH1 domain for catalysis and SH2 and SH3
domains that are involved in enzyme regulation. SH2 domains bind peptides that contain a
phosphoTyr (pTyr) residue embedded within an appropriate amino acid sequence. SH2
domain-targeted peptides activate members of the Src kinase family. A caged Lck SH2 peptide
ligand was synthesized using standard Fmoc solid phase synthesis on Rink resin as shown in
Scheme 3. The free amine of 5 was covalently modified with 4,5-dimethoxy-2-
nitrobenzaldehyde (Ar-CHO) to generate the corresponding imine, which was subsequently
reduced with NaBH3CN to furnish 6. The latter was ultimately converted into the caged SH2
ligand 8. The affinity of 8 (Kd = 127 μM) for Lck SH2 domain is 50-fold poorer than the
corresponding uncaged species (Kd = 2.6 μM), as determined by competition assay with a
previously described dapoxyl labeled peptide [75]. This backbone caging strategy should be
applicable to a variety of peptides and has been used to cage peptide substrates for PKA as
well as chymotrypsin. Two other SH2 domain-targeted peptides have been developed which
are caged at the phosphotyrosine group [76,77].
The above SH2 domain-directed strategy employs a peptide that converts an inactive form of
an enzyme into the active state. We’ve also developed an alternative approach in which an
activated form of the enzyme is trapped by a bivalent inhibitor, which holds the enzyme in
inhibitory stasis. Photolysis cleaves the bivalent inhibitor in half, eliminating inhibitory
potency and restoring enzymatic activity (Fig 5) [78]. Our lab has previously constructed a
high affinity bivalent inhibitor for the Src kinase (9) (Ki = 26 nM), which simultaneously binds
to both the SH1 and SH2 domains. Compound 9 displays a significantly enhanced affinity for
the Src kinase relative to its monovalent active site-directed counterpart (SH1 ligand IC50 =
1.9 μM) [79]. A small library of caged bivalent inhibitors was prepared with three different
photolabile moieties (10 – 12) placed at different locations in the peptide. The caged bivalent
peptide with the highest affinity for Src (IC50 = 18 nM) contains a photolabile group (13)
positioned in the middle of the sequence that links the SH1- and SH2-targeted ligands. Further
analysis of this peptide using a real time fluorescent assay[80,81] revealed that compound
13 inhibits Src kinase (pure enzyme or in cell lysates) almost completely at the appropriate
concentration (nM/μM boundary). Photolysis destroys this inhibitory activity. As noted above,
low molecular weight species, such as small caged peptides, display a high rate of diffusion.
Therefore, spot illumination of a caged low molecular compound in a living cell will not furnish
a long-lived spatially focused burst of an activated compound. The latter will simply diffuse
rapidly from the illuminated region. Although caging technology is commonly regarded as
furnishing the investigator with temporal and spatial control over biological activity, in reality
spatial control is only afforded with those molecules that diffuse slowly on the experimental
time scale. With the latter in mind, we inserted a cysteine residue into 13 and attached the
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peptide to PierceUltra link beads (14). Incubation of the Src kinase with the beads before and
after photolysis provided a direct assessment of Src’s ability to bind to the caged and uncaged
peptide beads, respectively. As expected, photolysis releases Src from the beads, which
suggests that spatial control is feasible by tethering caged low molecular species to slowly
diffusing supramolecular entities (e.g. a bead, organelle, membrane, etc).
Light-Dependent Peptide Antagonists of Enzymatic Activity
Inhibition of specific enzymes or disruption of protein-protein interactions provides a means
to correlate intracellular biochemistry with cellular behavior. However, many pathways
involve multiple timing requirements involving enzymatic activity, feed back loops, or
subcellular spatial localization. The spatiotemporal dynamics of these signaling pathways
cannot be fully understood without the ability inhibit a protein of interest with spatial and
temporal control. Photoactivatible inhibitors provide an off switch for intracellular protein
activity without altering endogenous protein expression levels [82–86]. The first example of
caged peptides designed to interfere with intracellular protein-protein interactions were
described by Walker et al in 1998 [87]. Antagonists that disrupt calmodulin binding to myosin
light chain kinase (MLCK) were derived from the calmodulin binding and autoinhibitory
domains of MLCK. The corresponding caged derivatives of these antagonist display 50-fold
weaker affinities than their uncaged counterparts for MLCK. Furthermore, these species block
cell motility in a light-dependent fashion. Since this initial report, several other groups have
utilized caged protein antagonists to investigate the role of specific proteins in cell-based
actions [77,88,89].
In conjunction with our caged PKA on switch construct (4), we synthesized a caged PKA
inhibitor that can serve as the corresponding off switch for PKA-dependent signaling pathways.
The design of the caged PKA antagonist was based on an active site-targeted sequence (Gly-
Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-amide) derived from an endogenous protein inhibitor of
PKA known as PKI [90,91]. The Ala residue in this sequence occupies the site reserved for
the phosphorylatable Ser or Thr in PKA substrates. The Arg plays a key role in promoting
active site binding [92,93]. Therefore modification of the Arg side chain with a photolabile
moiety should sharply reduce the inhibitory potency of the nonapeptide. The caged PKI
derivative 18 was prepared using the novel guanylating moiety 16, which was derived from S-
methylthiourea and a cloroformate derivative (15) of the common ortho-nitrobenzyl caging
group (Scheme 4). Guanylation of the ornithine residue in peptide 17 furnished the Arg caged
PKI inhibitor 18. To the best of our knowledge, this represents the first (and thus far, only)
report of a peptide caged at an Arg residue. Photolysis of 18 furnishes the active inhibitor 19
with a quantum yield of 0.023.
Enzymatic analysis of 18 confirmed that this caged species is a weaker PKA inhibitor (Ki =
20 μM) than its uncaged counterpart 19 (Ki = 420 nM) by almost two orders of magnitude.
Peptide 18 was microinjected into REF cells at an approximate intracellular concentration of
5 μM, below the Ki of the caged inhibitor. The caged inhibitor did not prevent the morphological
changes associated with activation of PKA by a cell permeable analog of cAMP, 8-(4-
chlorophenylthio)-cAMP (CPT-cAMP). However, upon UV irradiation at 300 – 400 nm, the
uncaged inhibitor blocked the CPT-cAMP-induced morphological changes. Caged PKA 4 and
the caged PKI inhibitor 18 can potentially serve as an on/off switch for addressing precise
temporal questions that pertain to PKA-mediated signaling cascades. However, in order for
both derivatives to be separately controlled in the same experiment the caged constructs need
to undergo photolysis at different wavelengths. Unfortunately, the latter is not feasible with
currently available caging moieties.
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Caged Sensors of Enzymatic Activity
The timing (both start point and duration) of intracellular enzymatic activity in response to a
stimulus can be useful in establishing a relationship between biochemical action and cellular
behavior. A large number of fluorescent probes have been developed that furnish real-time
visualization of intracellular enzymatic activity. Although powerful, these tools are at the
mercy of the biochemical activity of the cell, which may or may not be significant prior to
stimulation or may vary as a function of the cell cycle. In addition, whether a probe of protein
activity is microinjected or simply cell permeable, it takes time to load the agent into the cell.
Consequently, if basal activity is present, it becomes difficult to establish a precise t = 0.
Furthermore, it can be challenging to assess enzymatic activity during the course of a biological
event if the sensor becomes significantly depleted. Caged sensors provide investigators with
the means to load the reagent at their leisure and subsequently activate it once the cell has
reached the appropriate stage for analysis.
We have described a pyrene-based Src kinase sensor that displays a significant enhancement
in fluorescence upon phosphorylation [80]. However, the short excitation and emission
wavelengths associated with pyrene limits its usefulness in living cells. Therefore, a small
library of Src kinase peptide substrates containing Oregon green, cascade blue, or cascade
yellow was prepared. Src kinase-catalyzed phosphorylation of these substrates induces up to
a several fold enhancement in fluorescence. We subsequently prepared a caged version of one
of these species by covalently modifying the phosphorylatable tyrosine side chain with an
ortho-nitrobenzyl group (20). The caged sensor fails to serve as a Src substrate but can be
unleashed upon photolysis, where the duration of photolysis is directly correlated with the
amount of active sensor available for phosphorylation. The caged Src sensor 20 was
microinjected into the human carcinoma cell line A549, which is known to have high
expression levels of Src. As expected, time-dependent visualization of Src kinase activity is
photolysis-driven (Fig 6).
Protein kinase C (PKC) is implicated in many cellular processes including the G2/M transition
of mitosis, particularly around the time of nuclear envelope breakdown (NEB) [94–98]. We’ve
previously described a fluorophore-labeled PKC substrate that displays a 2.5 fold increase in
fluorescence upon phosphorylation [99]. However, since PKC is active in interphase cells, the
sensor is consumed before the activity of PKC can be tested during mitosis. Therefore, a caged
derivative (21) was prepared so that PKC activity can be precisely monitored at the time of
NEB [100,101]. In vitro assays with PKC demonstrated that peptide 21 doesn’t serve as a
substrate. However, after photolysis, a robust fluorescence increase is observed and the amount
fluorescence corresponds to the amount of sensor uncaged. Further analysis of 21 revealed a
maximal conversion to the uncaged sensor of 60% with a quantum yield of 0.06.
To address the question of when PKC is active during the G2/M transition during mitosis,
21 was microinjected into PtK2 cells along with a 70 kDa Texas red dextran. The latter is
excluded from the nucleus and thus provides a readily observable measure of NEB. PtK2 cells
remain relatively flat during mitosis (unlike most cell lines, which tend to round up), which
allows for ready identification of the stages of mitosis. Photoactivation of 21 during prophase
results in a time-dependent increase in fluorescence just prior to NEB. This is consistent with
phosphorylation of the peptide substrate, a direct barometer of PKC activity. Interestingly, the
observed real time fluorescence enhancement subsequently levels at the initiation of NEB. The
latter may represent a corresponding decrease in PKC activity during the nuclear envelope
breakdown event. However, the apparent absence of peptide phosphorylation during this stage
could also be due to complete phosphorylation of all photouncaged molecules. In order to
address the latter possibility, compound 21 was photo-converted to the active substrate after
NEB (Fig 7B). No fluorescence increase was observed under these conditions. These results
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are consistent with PKC activity prior to but not during or after NEB. Furthermore, the
introduction of PKC inhibitors during prophase not only blocks the expected fluorescence
increase but also prevents NEB. Consequently, PKC activity during prophase is required for
NEB. The active sensor is an excellent substrate for PKC α, β and γ. However, only α and β
are expressed in Ptk2 cells. In order to assess which PKC isoform is active just prior to NEB,
highly selective inhibitors for PKC α and β were co-injected with 21. These studies revealed
that PKC β is responsible for both the observed phosphorylation of the PKC sensor as well as
NEB itself.
Alteration of Gene Expression
Perturbation of signaling pathways in living organisms provides a means to correlate
biochemical activity with cell behavior within the context of a community of cells. However,
spatiotemporal control generally conveys a significantly different meaning at the organismal
level than at the cellular level. Spatial effects in the former commonly refer to differences in
the environment encompassing a cell or group of cells, be they different organs or
microenvironments within a specific organ. Temporal effects at the organismal level are
generally concerned with longer-lived phenomena than those within an individual cell. In
addition, there exist unique challenges associated with reagent delivery in multicellular
organisms. For example, although microinjection of a caged protein into single cells in culture
is routine, the corresponding delivery of intact proteins into cells in a multicellular organism
is far from routine. Indeed, given the looser time constraints associated with organismal biology
(versus cell biology), “protein delivery” is generally effected via introduction of genes (e.g.
via viral delivery), which are subsequently transcribed and translated. Alternatively, transgenic
animals have been constructed that possess genetic constructs that respond to small molecule
effectors. In 1996, No et al reported an especially effective small molecule gene expression
system, which has low levels of basal expression in the absence of the inducing agent, but
robust uniform expression and no toxicity in its presence [102]. The transgenic construct
consists of a constitutively expressed ecdysone receptor that, in combination with an
endogenously expressed retinoid X receptor, forms a heterodimer with the insect hormone
ecdysone (22) to induce expression of the transgene. Ecdysone, and the more potent plant
homolog ponasterone A, induce organism-wide expression of the specified gene in transgenic
organisms. We reasoned that it may be feasible to limit expression of the transgene to a single
cell (or a small cluster of cells) by using a combination of a caged ecdysteroid and a highly
focused light source.
We synthesized a photoactivatible ecdysone (23) designed to work in conjunction with the
ecdysteroid-inducible gene expression system [103]. The biological activity of ecdysone
requires a free hydroxyl group at C2. Caged ecdysone was prepared by generating the
dibutylstannylene acetal at the C2–C3 diol, followed by selective alkylation with an ortho-
nitrobenzyl derivative in the presence of CsF (Scheme 5). Covalent modification proceeds
exclusively at the equatorial C2 position to generate 23.
Our initial studies focused on the light-driven expression of luciferase. A transfected 293T cell
line was constructed, which constitutively express the ecdysone receptor, and contains a
luciferase gene driven by an ecdysone response element in its promotor. Ecdysone 22 induces
a 90-fold increase in luciferase expression, whereas, the caged form 23 exhibits a 6-fold
increase. By contrast, photolysis furnishes a 55-fold increase over non-stimulated luciferase
expression with maximal activity occurring after 16 h. Several hundred-fold changes in gene
expression are observed with the more potent ponasterone A analog of ecdysone. Spatially
discrete luciferase expression was monitored by incubating 293T cells with 23 followed by
spatially focused photolysis. As can be seen in Figure 8, luciferase expression is spatially
restricted to illuminated cells. These results validate the notion a small cell-permeable
Priestman and Lawrence Page 9













photosensitive compound (23) can be used to spatially control gene expression in a
multicellular environment.
Future Directions
Both the timing and location of signaling pathways can have significant consequences in terms
of biological behavior. We have constructed activators, inhibitors, and sensors of signaling
pathways that provide the means to control when and where a pathway is perturbed or probed.
Further advances in the field of caged biological molecules are required to sequentially switch
on and off signaling pathways or to activate multiple signaling pathways at multiple time points.
In order to achieve these possibilities, a family of caging moieties must be developed that
respond to unique wavelengths of light. Progress in the transfection of cells with peptides and
proteins is required to eliminate the need for microinjection. The latter will enable the use of
common techniques, such as western blots and flow cytometry, to analyze the biological
response. Finally, the acquisition of two-photon caging moieties, particularly those that can be
photoreleased in the 800 nm range, would be of profound utility for analysis in tissues and live
animals.
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Changes in morphology and stress fiber formation in REFs stained with phalloidin for F-actin
(Red) and FITC-IgG for microinjected cells (green). (A) REFs microinjected with caged PKA
4, (B) REFs microinjected with caged PKA 4 followed by photouncaging, (C) REFs
microinjected with free PKA catalytic subunit. Reprinted with permission from [66]. Copyright
1998 American Chemical Society.
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Design and synthesis of caged cofilin.
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Cleavage of F-actin filaments. (A) Rhodamine-labeled F-actin filaments (B) in the presence
of photoactivated cofilin. Reprinted with permission from [70]. Copyright 2002 American
Chemical Society.
Priestman and Lawrence Page 19














Local protrusions caused by activation of cofilin. (A) MTLn3 cells in serum after
microinjection of caged cofilin (B) Spatial uncaging of cofilin (C) 1 min after uncaging (D)
DAIS perimeter time-lapse images taken before and after photoactivation; showing site of
photoactivation (blue), protrusion (green) and retraction (red). From M. Ghosh, X. Song, G.
Mouneimne, M. Sidani, D.S. Lawrence, J.S. Condeelis, Cofilin promotes actin polymerization
and defines the direction of cell motility, 304, 2004, 743–746. Reprinted with permission from
AAAS.
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Photocleavable caged Src kinase activator. Reprinted with permission from [78]. Copyright
2008 American Chemical Society.
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Light-induced time-dependent change in fluorescence intensity in A549 cells microinjected
with caged Src sensor 20 (A) 1 min after uncaging and (B) 25 min after uncaging. Reprinted
with permission from [81]. Copyright 2006 American Chemical Society.
Priestman and Lawrence Page 22














Protein kinase activity prior to and after NEB. (A) Time course of phosphorylation of 21 prior
to NEB and (B) after NEB. Reprinted from Chemistry & Biology, 14, Z. Dai, N.G.
Dulyaninova, S. Kumar, A.N. Bresnick, D.S. Lawrence, Visual Snapshots of intracellular
kinase activity at the onset of mitosis, 1254–1260, copyright (2007) with permission from
Elsevier.
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Light-driven, spatially discrete luciferase espression. (A) Transfected 293T cells exposed to
22 (B) Transfected 293T cells exposed to 23 and spot illuminated (C) Transfected 293T cells
exposed to 23 outside illumination area. Reprinted from Chemistry & Biology, 9, W. Lin, C.
Albanese, R.G. Pestell, D.S. Lawrence, Spatially discrete, light-driven protein expression,
1347–1353. Copyright (2002) with permission from Elsevier.
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Mechanism of photolytic cleavage for the ortho-nitrobenzyl group.
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Synthesis of caged PKA.
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Synthesis of caged SH2 ligand.
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Synthesis of caged PKA inhibitor.
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Synthesis of caged ecdysone.
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